-+ 0.00%
-+ 0.00%
-+ 0.00%

Abbott Announces Commercial Availability Of Oncodetect Molecular Residual Disease Test

Benzinga·10/26/2026 13:08:52
Listen to the news

Abbott (NYSE: ABT) today announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular insights during and after cancer treatment.